Nachrichten zur Intellia Therapeutics Inc. Aktie

Leading genome editing market players include Merck KGaA, Horizon Discovery Ltd., Lonza Group Ltd., Twist Bioscience Corporation, Akron Biotech., CRISPR…

Intellia Therapeutics, Inc. (NTLA) Q3 2023 Earnings Call Transcript

…

Intellia Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation

…

Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases

TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Intellia Therapeutics,…

Intellia (NTLA) Misses on Q2 Earnings, Gives Pipeline Update

Intellias (NTLA) second-quarter earnings miss estimates. The company provides an update on its gene-editing pipeline....…

Form 8-K Intellia Therapeutics, For: Aug 03

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Intellia Therapeutics Q2 2023 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2023 Earnings and Company Updates

CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Insiderhandel: Aufsichtsrat verkauft Aktien von Intellia Therapeutics im Wert von 73.373$

Bhanji, Muna - Aufsichtsrat - Tag der Transaktion: 2023-07-06...…

Wall Street Expects Intellia Therapeutics Stock to Climb 107%. Is That Too Optimistic?

Pre-revenue biotechs dont have many ways to juice their share prices....…

Insiderhandel: EVP, Chief Technical Officer verkauft Aktien von Intellia Therapeutics im Wert von 225.000$

Clark, Eliana - Vorstand - Tag der Transaktion: 2023-06-20...…

Form 8-K Intellia Therapeutics, For: Jun 14

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intellia (NTLA) Up on Positive Data Updates From HAE Study

Intellias (NTLA) promising interim data on the early-stage study of NTLA-2002 shows potential as a single-dose treatment for hereditary angioedema....…

Intellia Therapeutics stock gains on CRISPR treatment results

Intellia Therapeutics Inc. NTLA shares gained 6.4% premarket on Monday after the clinical stage genome-editing company announced new data from…

Intellia Therapeutics Shares Rise After Reporting Data For CRISPR Treatment

Intellia Therapeutics Shares Rise After Reporting Data For CRISPR Treatment...…

Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)

CAMBRIDGE, Mass., June 11, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Can This Gene-Editing Stock Deliver 10X Returns?

Buying shares of Intellia Therapeutics might be a smart move....…

Form 8-K Intellia Therapeutics, For: Jun 05

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. From its Board of Directors

CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023

CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Are You Looking for a Top Momentum Pick? Why Intellia Therapeutics, Inc. (NTLA) is a Great Choice

Does Intellia Therapeutics, Inc. (NTLA) have what it takes to be a top stock pick for momentum investors? Lets find…

Wall Street Analysts Think Intellia Therapeutics, Inc. (NTLA) Could Surge 115.12%: Read This Before Placing a Bet

The consensus price target hints at an 115.1% upside potential for Intellia Therapeutics, Inc. (NTLA). While empirical research shows that…

Intellia (NTLA) Beats on Q1 Earnings, Gives Pipeline Update

Intellias (NTLA) first-quarter earnings beat estimates. The company provides updates on its gene-editing pipeline....…

Intellia jumps 13% after Q1 updates

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Lags Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 17.02% and 4.82%, respectively, for the quarter ended March 2023.…

Form 8-K Intellia Therapeutics, For: May 04

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Intellia Therapeutics Q1 2023 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities

CAMBRIDGE, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema

CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

dpa-AFX ProFeed